Efficacy and Safety of Erythropoiesis-Stimulating Proteins in Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis-Reference-Cited by-同舟云学术

Efficacy and Safety of Erythropoiesis-Stimulating Proteins in Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis

Published:2007-10-01 Issue:10 Volume:12 Page:1264-1273
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Ross Susan D.¹,Allen I. Elaine²,Probst Corey A.¹,Sercus Brian¹,Crean Sheila M.¹,Ranganathan Gayatri¹

Affiliation:

1. a United BioSource Corporation, Medford, Massachusetts, USA

2. b Babson College, Wellesley, Massachusetts, USA

Abstract

Learning Objectives After completing this course, the reader will be able to: Provide the current best estimates of hemoglobin response with erythropoiesis-stimulating proteins in anemia of MDS.Specify prognostic factors for response that are potentially useful.Describe the gaps in the existing evidence base regarding these agents in MDS. Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com

Funder

Amgen

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.12-10-1264

Reference48 articles.

1. Understanding the myelodysplastic syndromes;Kouides;The Oncologist,1997

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-synthetase and myelodysplastic syndromes with deep morphea: an example of shared immunopathogenesis? A case-based review;Rheumatology International;2024-09-09

2. Momelotinib in myelofibrosis and beyond: a comprehensive review of therapeutic insights in hematologic malignancies;Discover Oncology;2024-08-27

3. Androgen use in bone marrow failures and myeloid neoplasms: Mechanisms of action and a systematic review of clinical data;Blood Reviews;2023-11

4. Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data;Turkish Journal of Hematology;2023-05-30

5. Practical aspects of the use of erythropoiesis-stimulating agent in patients with hematological malignancy;Meditsinskiy sovet = Medical Council;2022-10-06